Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R and D Committee
Read Article
News
2024
2023
Archive
Search news articles
July 10, 2018
Rare endocrine disease biotech Crinetics Pharmaceuticals sets terms for $80 million IPO
June 26, 2018
NodThera secures £28 million ($40 million) Series A Financing
June 26, 2018
ZEMDRI (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)
June 23, 2018
IMPEL NEUROPHARMA ANNOUNCES FDA CLEARANCE OF IND FOR PIVOTAL PHASE 3 STUDY OF INP104 FOR ACUTE TREATMENT OF MIGRAINE
June 21, 2018
Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly
June 15, 2018
Nohla Announces Presentation of Dilanubicel (NLA101) Data at EHA Annual Meeting Showcasing Excellent Long-term Survival Outcomes
June 8, 2018
Phase 2 Study Shows Promising Results for Potential Mucus Clearance Drug
June 7, 2018
Spyryx SPX-101 Phase 2 HOPE-1 Trial Shows Improvement in Lung Function in Patients with Cystic Fibrosis via Novel Modulation of ENaC
June 6, 2018
Nohla Receives EMA PRIME Designation for Dilanubicel (NLA101) to Treat Hematopoietic Stem Cell Transplant Patients
June 5, 2018
Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy
« Previous Page
1
…
60
61
62
63
64
…
103